1,138 Shares of IDEXX Laboratories, Inc. $IDXX Bought by Invariant Investment Management

Invariant Investment Management purchased a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 1,138 shares of the company’s stock, valued at approximately $590,000.

A number of other institutional investors have also recently made changes to their positions in the stock. J. Stern & Co. LLP increased its stake in shares of IDEXX Laboratories by 23,694.7% in the fourth quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company’s stock worth $1,795,072,000 after buying an additional 2,642,200 shares during the period. Bank of New York Mellon Corp purchased a new stake in IDEXX Laboratories during the 2nd quarter valued at $628,223,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in IDEXX Laboratories by 4.6% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 911,489 shares of the company’s stock valued at $479,844,000 after buying an additional 39,700 shares during the period. Arrowstreet Capital Limited Partnership grew its holdings in IDEXX Laboratories by 52.4% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 838,839 shares of the company’s stock worth $471,335,000 after acquiring an additional 288,471 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of IDEXX Laboratories by 4.3% in the first quarter. Dimensional Fund Advisors LP now owns 573,332 shares of the company’s stock valued at $322,145,000 after acquiring an additional 23,582 shares during the period. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Barclays lowered their price objective on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research note on Tuesday, August 11th. UBS Group upped their price target on IDEXX Laboratories from $620.00 to $670.00 and gave the company a “neutral” rating in a research report on Wednesday, August 5th. Citigroup lifted their price objective on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 5th. Wall Street Zen cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Finally, Weiss Ratings downgraded IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, August 27th. Six equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $747.00.

Insider Activity

In other news, Director Lawrence D. Kingsley sold 2,203 shares of the business’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $532.08, for a total value of $1,172,172.24. Following the sale, the director directly owned 9,568 shares of the company’s stock, valued at $5,090,941.44. The trade was a 18.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.79% of the company’s stock.

IDEXX Laboratories Stock Up 1.3%

Shares of NASDAQ IDXX traded up $6.47 during mid-day trading on Thursday, hitting $513.14. 696,661 shares of the stock traded hands, compared to its average volume of 570,248. The company has a market cap of $40.43 billion, a price-to-earnings ratio of 36.09, a PEG ratio of 2.75 and a beta of 1.55. The stock has a fifty day moving average price of $539.78 and a 200-day moving average price of $553.31. IDEXX Laboratories, Inc. has a 52 week low of $500.61 and a 52 week high of $769.98. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.17.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, beating the consensus estimate of $3.94 by $0.33. The business had revenue of $1.22 billion during the quarter, compared to analyst estimates of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The company’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same quarter last year, the firm posted $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Research analysts anticipate that IDEXX Laboratories, Inc. will post 14.81 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology and water-testing products and services. The company primarily serves the companion animal veterinary market, helping veterinary practices diagnose and manage diseases through laboratory testing, in-house analyzers, diagnostic kits, imaging systems, software and related consumables.

IDEXX’s companion animal offerings include its IDEXX Reference Laboratories, IDEXX VetLab instruments and software, SNAP rapid tests, and practice-management and data solutions.